Writing for the World Economic Forum (WEF), Nigel Cory and WEF Digital Trade Fellow Mike Gallaher, summarize a recent report they authored for WEF that enumerates key steps policymakers should take to support cross-border payments and digital trade growth.
Publications
June 4, 2020
Big Internet, like other advanced industries like Big Auto, Big Aerospace, and Big Pharma, plays a key role in driving U.S. competitiveness, innovation, job creation, and economic growth. As such, policymakers should be careful to not cripple this engine of U.S. prosperity.
June 4, 2020
Just because DSTs may be attractive to individual countries doesn’t make them good policy. In fact, they are bad policy. A central goal of good tax policy should be to treat similar transactions the same way. DSTs violate this principle in a number of ways.
June 3, 2020
Trump should be careful of what he asks for because striking down Section 230 could very well have the opposite effect of what he intends.
June 2, 2020
A World Economic Forum report—produced with extensive research contributions from ITIF—analyzes key barriers and challenges to cross-border payments and recommends how to overcome them to support global trade.
June 1, 2020
AI-related publications increased 10 percent annually from 2005 to 2015, growing to 23 percent a year from 2015 to 2018.
June 1, 2020
No, markups have increased only slightly in some industries—and have stayed the same overall—which refutes claims that market concentration is giving firms more pricing power.
June 1, 2020
The COVID-induced isolation economy has demonstrated just how important broadband networks are for work, learning, and entertainment. But it has also highlighted important gaps, such as the rural divide and the “homework divide,” that government policy can play a role in filling.
May 27, 2020
As long as the Wall Street triumphalists’ unreflected “why worry?” thinking remains the norm, the urgently needed pursuit of a U.S. economic reform agenda will go nowhere.
May 27, 2020
In contrast to what critics might assert, now is not the time to undermine either the IP rights or reasonable pricing reimbursement approaches that have underpinned so much successful biomedical innovation, and which will be key to getting through this crisis.